Department of Public Health, University of Rome Tor Vergata, Rome, Italy.
Infection. 2011 Aug;39(4):367-70. doi: 10.1007/s15010-011-0127-3. Epub 2011 Jun 15.
We report a case of an immunocompromised patient affected by chronic hepatitis B virus (HBV) with high basal HBV viremia (>8 log(10) IU/ml) who failed an entecavir regimen, despite the absence of primary or secondary drug resistance mutations. The patient achieved sustained virological success (serum HBV DNA <12 IU/ml) when tenofovir was added to the treatment. This case highlights the difficulty in choosing an optimal therapy in such specific conditions and supports the concept of tailoring therapy (including combination regimens) on the basis of the particular conditions of each individual patient.
我们报告了一例免疫功能低下的慢性乙型肝炎病毒（HBV）感染患者，其基础 HBV 病毒载量较高（>8 log(10) IU/ml），尽管不存在原发性或继发性耐药突变，但恩替卡韦治疗失败。当替诺福韦加入治疗时，患者获得了持续的病毒学应答（血清 HBV DNA <12 IU/ml）。该病例突出了在这种特殊情况下选择最佳治疗方案的困难，并支持根据每个患者的具体情况制定治疗方案（包括联合治疗方案）的概念。
